6 citations
,
May 2013 in “Journal of Clinical Oncology” Combining Ficlatuzumab and Gefitinib can cause severe hair loss.
August 2026 in “Clinical Cosmetic and Investigational Dermatology” In this study, pegylated interferon alpha therapy was independently associated with more severe hair loss, particularly acute telogen effluvium, in chronic hepatitis B patients with alopecia, compared to nucleos(t)ide analog therapy, emphasizing the importance of monitoring and counseling, especially for younger female patients.
2 citations
,
November 2024 in “In Silico Pharmacology” 4 citations
,
August 2005 in “Clinical Infectious Diseases” This case report highlights that treating a patient with high doses of ascorbic acid quickly resolved scurvy-associated leg edema and purpura, illustrating the deficiency's impact in developed countries.
38 citations
,
August 1999 in “New England journal of medicine/The New England journal of medicine” This letter discusses observations of indinavir's effects on skin, likening them to those of retinoids, but does not present new clinical findings.
June 2020 in “Jurnal Penyakit Dalam Indonesia” This case study highlights that primary biliary cholangitis in a patient with systemic lupus erythematosus can respond well to ursodeoxycholic acid therapy, and anti-DFS70 findings may require further evaluation for other nonsystemic autoimmune conditions.
December 2013 in “Urology reports (St - Petersburg)” This study found that Sonirid Duo, a combination of tamsulosin and finasteride, significantly improved symptoms and quality of life in patients with BPH over 12 months.
April 2023 in “Tikrit Journal of Pharmaceutical Sciences” In this study, researchers assessed the effects of deferasirox in 85 children with ß-thalassemia in Kirkuk and reported that while 55.3% experienced a reduction in serum ferritin, 9.4% had adverse effects, indicating that deferasirox is generally well-tolerated as an iron chelator with modifiable side effects.
1 citations
,
July 2024 in “Journal of Investigative Dermatology” VYN201 shows promise as a safe and effective treatment for non-segmental vitiligo.
July 2025 in “International Journal of Health and Medicine” In this study, dual therapy with tamsulosin and solifenacin significantly improved urinary symptom severity and bladder capacity in BPH patients, but did not alter post-void residual urine volume. This supports using the combination therapy for managing LUTS, especially for storage-related symptoms, in clinical settings.
37 citations
,
October 2017 in “Clinical and Experimental Dermatology” This article discusses the potential of oral tofacitinib as a treatment for atopic dermatitis, alopecia areata, and vitiligo, without presenting new clinical results.
3 citations
,
August 2021 in “Clinical Case Reports” This case report describes a patient with a NUDT15 minor variant who experienced severe myelosuppression due to azathioprine, emphasizing typical symptoms as clues to the adverse reaction.
9 citations
,
October 2015 in “Cutaneous and ocular toxicology” This case report observed vemurafenib-induced pityriasis amiantacea, a scalp scaling reaction, in a patient with metastatic melanoma, which was managed symptomatically without altering vemurafenib treatment.
13 citations
,
October 2017 in “Bioorganic & Medicinal Chemistry” This study found that compound 3, a tetrahydropyridoindole carboxymethylated at position 5, significantly inhibited sorbitol accumulation in both rat eye lenses and tissues affected by diabetes, indicating its potential as a lead compound for ALR2 inhibition.
73 citations
,
October 2001 in “Epilepsia” In this study, valproic acid treatment was associated with reduced biotinidase activity and improved skin lesions after biotin supplementation in children with seizures.
October 2025 in “Influenza and Other Respiratory Viruses” This study found that bis-benzylisoquinoline and Amaryllidaceae alkaloids, especially aromoline, show potential as antiviral agents, suggesting they could serve as foundations for developing new treatments against coronaviruses by enhancing the understanding of their structure-activity relationships.
June 2026 in “Open Access Research Journal of Biology and Pharmacy” This study used molecular docking simulations to identify approved drugs, including Bedaquiline and Telmisartan, with potential to treat Onchocerca volvulus infections by inhibiting key protein targets, suggesting these drugs could be repurposed for onchocerciasis treatment with further validation.
September 2023 in “Small animal advances” This case report from Veterinary Clinical Complex, Kurumbapet, India, described a kitten with superficial dermatophytosis caused by Microsporum spp., which was successfully treated using itraconazole syrup, cetirizine, and a liver-supportive syrup, achieving complete recovery by the third week without adverse effects.
February 2025 in “International Journal of STD & AIDS” In this case report, a patient with HIV developed hirsutism after starting tofacitinib for alopecia areata, which resolved upon medication discontinuation and laser hair removal.
12 citations
,
March 2022 in “Dermatologic Therapy” This report presents a case of a patient developing new multiple sclerosis while using tofacitinib for alopecia areata, noting no new comprehensive research findings.
74 citations
,
February 2018 in “Journal of the American Academy of Dermatology”
January 2021 in “Anais do Congresso Brasileiro de Reumatologia 2020” In this case report, tofacitinib led to significant improvement in arthritis and partial improvement in alopecia for a female patient with systemic lupus erythematosus, with no observed adverse effects.
8 citations
,
January 2023 in “Journal of Research in Pharmacy” This study suggests that compounds from turmeric and bitter have potential antiviral activity against the influenza A virus by inhibiting the polymerase PA-PB1, warranting further experimental verification.
December 2025 in “Journal of Pakistan Association of Dermatologists” This case report highlights a rare instance of erosive pustular dermatosis of the scalp in a patient on afatinib, underlining the importance of early recognition and management of this adverse effect.
9 citations
,
March 2022 in “Journal of Chemical Information and Modeling” This study identified a series of novel β-glucuronidase inhibitors that may help mitigate adverse effects of first-line anti-cancer drugs by targeting gut bacteria, based on virtual high-throughput screening findings.
January 2014 in “대한피부과학회지” This case study in a hepatitis B patient observed that pegylated interferon alpha2a treatment may induce localized alopecia areata, which appeared to correlate with treatment administration and discontinuation.
In this study, researchers evaluated 27 drugs for antifungal activity against Cryptococcus strains and found that some antiparasitics and antidepressants showed potential by reducing fungal growth and capsule size, with particular enhancements when combined with fluconazole.
May 2024 in “Pigment International” In a randomized phase 2b clinical trial, oral ritlecitinib significantly reduced facial vitiligo area scores in patients with active nonsegmental vitiligo compared to placebo, with a favorable safety profile observed over 48 weeks, suggesting its potential as an effective treatment option (Ezzedine et al., 2023).
January 2022 in “International Journal of Research Publications” In this case report, an 8-year-old child with tinea capitis caused by Microsporum canis showed significant clinical and mycological improvement after a four-week course of oral griseofulvin, highlighting the importance of comprehensive diagnostic examinations to confirm the diagnosis and determine the best treatment.
11 citations
,
January 1999 in “Dermatology”